CTXT Pty Ltd.
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Sep 2035
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 24, 2027The maintenance fee for Tetrahydroisoquinolines as PRMT5 inhibitors (US 10,421,743) comes due Mar 24, 2027. Unpaid by Sep 24, 2027, it lapses early.
- 2 fees due Jun 3 to 30, 2027 · next Jun 3
- 2 fees due Aug 4 to 27, 2027 · next Aug 4
- 1 fee due Nov 12, 2027The maintenance fee for Tetrahydroisoquinoline derived PRMT5-inhibitors (US 10,647,708) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,005,792 | Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 10,494,376 | Tetrahydroisoquinoline derived PRMT5-inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 10,647,708 | Tetrahydroisoquinoline derived PRMT5-inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 10,421,743 | Tetrahydroisoquinolines as PRMT5 inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 10,519,167 | 3-oxa-8-azabicyclo[3.2.1]octane derivatives and their use in the treatment of cancer and hemoglobinopathies In force · From the USPTO record | In force | From the USPTO record | |
| US 10,550,096 | Tetrahydroisoquinolines as PRMT5 inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 11,028,101 | 3-oxa-8-azabicyclo[3.2.1]octane derivatives and their use in the treatment of cancer and hemoglobinopathies In force · From the USPTO record | In force | From the USPTO record | |
| US 10,787,434 | Benzopiperdine derivatives and their use in the treatment of cancer and hemoglobinopathies In force · From the USPTO record | In force | From the USPTO record | |
| US 10,961,256 | PRMT5 inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 10,745,380 | Pyridine derivatives and their use in the treatment of cancer and hemoglobinopathies In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 18: 2 patents in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 2 abandoned · 4 no status recorded